m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00026)
Name
Riccardin C
Synonyms
Riccardin C; Riccardi C; CHEMBL411317; BDBM23839
    Click to Show/Hide
Status
Investigative
Structure
Formula
C28H24O4
InChI
1S/C28H24O4/c29-22-9-13-24-21(17-22)8-3-18-4-10-23(11-5-18)32-28-16-20(7-14-26(28)30)2-1-19-6-12-25(24)27(31)15-19/h4-7,9-17,29-31H,1-3,8H2
InChIKey
JMKSVONWZFVEAI-UHFFFAOYSA-N
PubChem CID
10070992
TTD Drug ID
D00HVP
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Oxysterols receptor LXR-alpha (NR1H3)
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Oxysterols receptor LXR-alpha (NR1H3) is a therapeutic target for Riccardin C. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of Riccardin C through regulating the expression of Oxysterols receptor LXR-alpha (NR1H3). [1], [2]
References
Ref 1 EGFR/SRC/ERK-stabilized YTHDF2 promotes cholesterol dysregulation and invasive growth of glioblastoma. Nat Commun. 2021 Jan 8;12(1):177. doi: 10.1038/s41467-020-20379-7.
Ref 2 Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis. J Med Chem. 2008 Nov 27;51(22):7161-8. doi: 10.1021/jm800799q.